Risk factors for medication-related osteonecrosis of the jaw and salivary IL-6 IN cancer patients.
Biomarkers in saliva
Bisphosphonates
Interleukin-6
Osteonecrosis of the jaw
Journal
Brazilian journal of otorhinolaryngology
ISSN: 1808-8686
Titre abrégé: Braz J Otorhinolaryngol
Pays: Brazil
ID NLM: 101207337
Informations de publication
Date de publication:
Historique:
received:
22
06
2020
revised:
10
08
2020
accepted:
14
09
2020
pubmed:
16
11
2020
medline:
20
9
2022
entrez:
15
11
2020
Statut:
ppublish
Résumé
Medication-related osteonecrosis of the jaws is a severe complication of the use of antiresorptive and antiangiogenic therapy, with limited treatment options and great impact on patient's quality pf life. The aim of this study was to assess the risk factors associated with medication-related osteonecrosis of the jaws in oncologic patients undergoing bisphosphonate treatment. In addition, salivary levels of interleukin-6, IL-6, were measured to investigate their association with severity and risk of medication-related osteonecrosis of the jaws. Case-control study with 74 patients with bone metastases from solid tumors and multiple myeloma was included. Patients were divided into three groups: 1) those undergoing bisphosphonate treatment with medication-related osteonecrosis of the jaws; 2) those undergoing bisphosphonate without medication-related osteonecrosis of the jaws; and 3) those with bisphosphonate pretreatment. The demographic and medical data of the patients were collected to assess risk. The clinical evaluation was performed to diagnose medication-related osteonecrosis of the jaws and unstimulated saliva was collected for quantification of IL-6. As result, it was observed that patients diagnosed with medication-related osteonecrosis of the jaws were submitted to higher number of bisphosphonate doses (p = 0.001) and monthly infusion protocol (p = 0.044; OR = 7.75). Patients who did not have routine followup with specialized dentists during therapy with bisphosphonate and smoking were associated with medication-related osteonecrosis of the jaws (p = 0.019; OR = 8.25 and p = 0.031; OR = 9.37 respectively). Group 1 had a higher frequency of treatment with chemotherapy and corticosteroids concomitant with bisphosphonate, and surgical dental procedures (p = 0.129). Salivary IL-6 levels showed no statistically significant difference between the groups (p = 0.571) or association with medication-related osteonecrosis of the jaws severity (p = 0.923). A higher number of bisphosphonate cycles, monthly infusion protocol, no dental follow-up for oral health maintenance and smoking were associated with medication-related osteonecrosis of the jaws. Specialized dental follow up during bisphosphonate treatment has been shown to be an important factor in preventing this complication.
Identifiants
pubmed: 33189595
pii: S1808-8694(20)30176-2
doi: 10.1016/j.bjorl.2020.09.010
pmc: PMC9483935
pii:
doi:
Substances chimiques
Diphosphonates
0
Interleukin-6
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
683-690Informations de copyright
Copyright © 2020 Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. Published by Elsevier Editora Ltda. All rights reserved.
Références
BMJ Open. 2019 May 22;9(5):e025600
pubmed: 31122970
Am J Clin Oncol. 2012 Aug;35(4):386-92
pubmed: 22561331
Clin Pharmacol Ther. 2010 Apr;87(4):483-7
pubmed: 20182422
J Oral Maxillofac Surg. 2005 Nov;63(11):1567-75
pubmed: 16243172
Int J Oral Sci. 2014 Dec;6(4):219-26
pubmed: 25105817
Ann Oncol. 2012 May;23(5):1341-1347
pubmed: 21986094
Ann Oncol. 2009 Jan;20(1):117-20
pubmed: 18689864
J Oral Maxillofac Surg. 2008 Apr;66(4):625-31
pubmed: 18355585
Eur J Orthop Surg Traumatol. 2015 Feb;25(2):211-5
pubmed: 24879610
Ann N Y Acad Sci. 1993 Sep 20;694:72-7
pubmed: 8215087
J Craniomaxillofac Surg. 2012 Jun;40(4):303-9
pubmed: 21676622
J Dent Res. 2015 Apr;94(4):534-9
pubmed: 25710950
Clin Oral Investig. 2013 May;17(4):1259-66
pubmed: 22864527
Leukemia. 2007 Jul;21(7):1545-8
pubmed: 17410188
J Oral Maxillofac Surg. 2014 Oct;72(10):1938-56
pubmed: 25234529
J Oral Maxillofac Surg. 2004 May;62(5):527-34
pubmed: 15122554
Oral Dis. 2014 Jul;20(5):446-52
pubmed: 23837828
Pharmacol Ther. 2014 Feb;141(2):125-39
pubmed: 24076269
Anticancer Res. 2014 May;34(5):2477-80
pubmed: 24778063
J Periodontal Res. 2011 Feb;46(1):39-47
pubmed: 20701670
Med Oral Patol Oral Cir Bucal. 2013 Mar 01;18(2):e194-200
pubmed: 23229272
Cancer Treat Rev. 2015 May;41(5):455-64
pubmed: 25913713
Bone. 2009 Nov;45(5):843-52
pubmed: 19631301
J Korean Assoc Oral Maxillofac Surg. 2019 Apr;45(2):108-115
pubmed: 31106139
Eur Urol. 2008 Nov;54(5):1066-72
pubmed: 18602738
J Oral Pathol Med. 2013 May;42(5):405-8
pubmed: 23157469
Osteoporos Int. 2019 Jan;30(1):231-239
pubmed: 30406309
Cancer. 2005 Jul 1;104(1):83-93
pubmed: 15929121
J Oral Maxillofac Surg. 2010 Sep;68(9):2241-7
pubmed: 20728033
Med Oral Patol Oral Cir Bucal. 2012 Nov 01;17(6):e948-55
pubmed: 22926469
JAMA Oncol. 2017 Jul 01;3(7):906-912
pubmed: 28125763
J Clin Oncol. 2005 Dec 1;23(34):8580-7
pubmed: 16314620
J Clin Densitom. 2017 Jan - Mar;20(1):8-24
pubmed: 27956123